Simon Agwale

Simon Agwale, Ph. D is the CEO of Innovative Biotech, Nigeria and Innovative Biotech USA Inc. He is a member of the board of the African Vaccine Manufacturers’ Initiative (AVMI) and in 2019 was asked to lead their Covid-19 Vaccine Task Team. He is also an advisor to WAHO, and part of a recently established ECOWAS vaccines taskforce. He is currently the Lead (Technology and IP) of Partnership for Africa Vaccines Manufacturing (PAVM) of Africa Centers for Disease Control (AfricaCDC).
Dr. Agwale has a vision for the development and investigation of HIV vaccine constructs from prevalent Nigerian strains which are relevant to Nigerians. He is also currently developing novel vaccines against Covid-19, Ebola, cervical cancer, and HIV using innovative viral-like particles (VLPs). Through INNOVATIVE, Dr. Agwale is striving to further develop and refine these dynamic, novel treatments, and in doing so, expand domestic vaccine manufacturing capabilities in Nigeria to serve the African community.
Dr. Agwale was a Postdoc fellow at the Institute of Human Virology Baltimore, USA and Visiting Scientist at various institutions in Brazil, Germany, UK including the US Vaccine Research Center/NIH, and US Center for Disease Control and prevention in Atlanta. Dr. Agwale was West Africa’s representative on HIV/AIDS for Developing countries Coordinating Committee (DCCC) at European and Developing Countries Clinical Trials Programme, where he was also the chair of the African Scientists committee (DCCC). He is a recipient of several scholarships, fellowships and grants from reputable organizations around the world. He has also authored and co-authored numerous noteworthy publications.

business meeting

The Post-COVID-19 State of Biomanufacturing News from the Biotech Start-up Symposium

During last month’s Biotech Start-up Symposium, attendees heard an all-star team of experts discuss the intricacies of raising…

Scroll to Top